Norway Multiomics Market Size & Outlook, 2026-2033
Global Market
Related Markets
Norway multiomics market highlights
- The Norway multiomics market generated a revenue of USD 8.0 million in 2025 and is expected to reach USD 15.4 million by 2033.
- The Norway market is expected to grow at a CAGR of 8.5% from 2026 to 2033.
- In terms of segment, bulk multiomics was the largest revenue generating type in 2025.
- Single-cell Multiomics is the most lucrative type segment registering the fastest growth during the forecast period.
Multiomics market data book summary
| Market revenue in 2025 | USD 8.0 million |
| Market revenue in 2033 | USD 15.4 million |
| Growth rate | 8.5% (CAGR from 2026 to 2033) |
| Largest segment | Bulk multiomics |
| Fastest growing segment | Single-cell Multiomics |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single-cell Multiomics, Bulk Multiomics |
| Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Danaher Corp, Shimadzu Corp, Bruker Corp, Qiagen NV, Agilent Technologies Inc, BD, Revvity Inc, BGI Group |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global multiomics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, UK multiomics market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,008.9 million by 2033.
Increasing funding related to gene therapy in the country is expected to create growth opportunities for market growth. For instance, in December 2022, Haapaniemi group approved around USD 2 million (NOK 20 million) to develop a clinical trial with genome-edited T cells.
This initiative aims to develop Tcell therapy for STwAT1 Gain-of-Function disorder and other immunodeficiencies. On the other hand, the Norwegian government recognized the importance of multiomics research and provided support through funding and initiatives aimed at promoting scientific research & innovation.
For instance, the Clinical and Multi-omic (CAMO) cohort, a part of the Norwegian Women and Cancer (NOWAC) study performed in February 2023, involved collecting comprehensive epidemiological and clinical information, along with blood and tumor samples, to establish a cohort conducive to integrated research approaches.
No credit card required*
Publish Date: Jun 12, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Multiomics Market Scope
Multiomics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Shimadzu Corp | View profile | 15,284 | 1, Nishinokyo-Kuwabara-cho, Nakagyo-ku, Kyoto, Japan, 604-8511 | www.shimadzu.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Revvity Inc | View profile | 11,500 | 940 Winter Street, Waltham, MA, United States, 02451 | www.revvity.com |
| Bruker Corp | View profile | 9,707 | 40 Manning Road, Billerica, MA, United States, 01821 | www.bruker.com |
| BD | View profile | 10001+ | Franklin Lakes, New Jersey, United States, North America | www.bd.com |
| BGI Group | View profile | 5001-10000 | Shenzhen, Guangdong, China, Asia | www.genomics.cn/ |
Norway Multiomics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Multiomics Market Outlook will help companies and investors design strategic landscapes.
Bulk Multiomics was the largest segment with a revenue share of 73.75% in 2025.
Horizon Databook has segmented the Norway multiomics market based on single-cell multiomics, bulk multiomics covering the revenue growth of each sub-segment from 2021 to 2033.
Increasing funding related to gene therapy in the country is expected to create growth opportunities for market growth. For instance, in December 2022, Haapaniemi group approved around USD 2 million (NOK 20 million) to develop a clinical trial with genome-edited T cells.
This initiative aims to develop Tcell therapy for STwAT1 Gain-of-Function disorder and other immunodeficiencies. On the other hand, the Norwegian government recognized the importance of multiomics research and provided support through funding and initiatives aimed at promoting scientific research & innovation.
For instance, the Clinical and Multi-omic (CAMO) cohort, a part of the Norwegian Women and Cancer (NOWAC) study performed in February 2023, involved collecting comprehensive epidemiological and clinical information, along with blood and tumor samples, to establish a cohort conducive to integrated research approaches.
- Norway Multiomics Market Type Outlook (Revenue, USD Million , 2021-2033)
- Single-cell Multiomics
- Bulk Multiomics
- Norway Multiomics Market Platform Outlook (Revenue, USD Million , 2021-2033)
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
- Norway Multiomics Market Product & Service Outlook (Revenue, USD Million , 2021-2033)
- Services
- Product
- Norway Multiomics Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical & Biotechnology Companies
- Others
- Academic & Research Institutes
- Norway Multiomics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Immunology
- Cell Biology
- Oncology
- Neurology
Reasons to subscribe to Multiomics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Multiomics Market Outlook databook
- Our clientele includes a mix of Multiomics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway Multiomics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway Multiomics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Norway Multiomics Market, 2021-2033 (US$M)
Norway Type - Multiomics Market Statistics, 2025 - 2033 (US$M)
